And now let's take a listen to Dr. Brian Miller.

So in this section, we'll continue to discuss second-generation antipsychotic LAIs in clinical practice, focusing on paliperidone and risperidone.

There are multiple formulations of paliperidone palmitate.

We'll begin by talking about Invega Sustenna, the first form.

The typical starting dose for Invega Sustenna is two hundred and thirty-four milligrams given on day one, and then a hundred and fifty-six milligrams given on day eight by deltoid injection.

In contrast to other agents, oral supplementation is not required, and the typical maintenance doses for Invega Sustenna are thirty-nine, seventy-eight, one seventeen, one fifty-six, or two hundred and thirty-four milligrams given every four weeks by deltoid or gluteal injection.

In terms of dose equivalency, three milligrams of oral paliperidone corresponds to between thirty-nine and seventy-eight milligrams of the LAI.

And with that, let's take a listen now to Dr. Brian Miller.

So in our next section now, we'll talk about the use of LAIs in clinical practice, specifically formulations of aripiprazole and olanzapine.

So we'll begin talking about these two second-generation agent LAIs.

We'll begin with aripiprazole monohydrate, also known as Abilify Maintena.

The typical starting dose is three hundred to four hundred milligrams monthly, given by deltoid or gluteal injection.

Oral supplementation should be continued for fourteen days, and a typical maintenance dose is essentially the same as the starting dose, three hundred milligrams to four hundred milligrams every three to four weeks.

In terms of dose equivalency, ten milligrams of oral aripiprazole corresponds to approximately three hundred milligrams of LAI every month, and doses at or above fifteen milligrams a day of oral aripiprazole would correspond to an LAI dose of four hundred milligrams per month.

And now let's take a listen to Dr. Miller.

Let's talk about understanding when to prescribe long-acting injectable antipsychotics.

We'll begin by talking about their approved indications.

First of all, all second-generation agent LAIs are approved for the treatment of schizophrenia.

Paliperidone palmitate is specifically approved for schizoaffective disorder, either as monotherapy or in adjunct to mood stabilizers or antidepressants.

Risperidone microspheres are approved for bipolar I disorder, specifically maintenance treatment, either as monotherapy or as an adjunct to lithium or valproate.

And both of the first-generation antipsychotic LAIs are approved for patients requiring prolonged parental antipsychotic therapy.